Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Biotechnology firms are increasingly focusing on innovative drug-delivery platforms as the cost of developing new drugs skyrockets and regulatory hurdles become tougher. This shift is attracting significant investor interest, as the market for these advanced delivery technologies is projected to reach $410 billion. By optimizing existing therapies through better delivery methods, companies aim to maximize efficacy while reducing costs, highlighting a strategic pivot in the biotech sector with substantial implications for future industry dynamics.